Notice of Intent to Publish a Funding Opportunity Announcement for Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
Notice Number:

Key Dates

Release Date:
June 14, 2022
Estimated Publication Date of Funding Opportunity Announcement:
November 16, 2022
First Estimated Application Due Date:
March 01, 2023
Earliest Estimated Award Date:
November 01, 2023
Earliest Estimated Start Date:
December 01, 2023
Related Announcements


Issued by

National Institute on Drug Abuse (NIDA)


The National Institute on Drug Abuse intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for research on mechanisms of inflammasome activation and its link to immune functions in people with HIV and substance use disorders. 

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. 

The FOA is expected to be published in Fall 2022 with an expected application due date in Spring 2023.

This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

Research Initiative Details

This Notice informs the research community of this new initiative and encourages investigators with expertise and insights into this area of exploring inflammasome and immune functions pertinent to myeloid cells in context of substance use and HIV to begin to consider applying for this new FOA.

In addition, research exploring inflammasome and immune functions pertinent to myeloid cells in context of substance use and HIV will be encouraged..

Among the areas of research encouraged in this initiative are understanding the involvement of myeloid cells regulated inflammasome activation, cross interactions with humoral adaptive immunity, and interplays among myeloid cells and neurons as well as other CNS resident cells that may help identify molecular markers and CNS immune cells associated with HIV-1 infection, latency, or disease progression among substance abuse populations, and identify novel therapies to treat neuroinflammation and immune dysregulation aroused in these processes.  

Funding Information


Estimated Total Funding

NIDA intends to commit $4M for FY 23

Expected Number of Awards
Estimated Award Ceiling


Primary Assistance Listing Number(s)


Anticipated Eligible Organizations
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Regional Organization
Eligible Agencies of the Federal Government

Applications are not being solicited at this time. 


Please direct all inquiries to:

Shang-Yi Anne Tsai, Ph.D.

National Institute on Drug Abuse


Yu Lin, Ph.D.

National Institute on Drug Abuse